A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs LYC 55716 (Primary)
- Indications Cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms ARGON
- Sponsors Lycera
- 15 Dec 2016 Status changed from not yet recruiting to recruiting.
- 13 Dec 2016 Status changed from active, no longer recruiting to not yet recruiting.
- 01 Dec 2016 Status changed from not yet recruiting to active, no longer recruiting.